cord-252123-z8c14q5d	2020	
cord-253552-qreg4emx	2020	
cord-258581-46p0k9lc	2020	Recently, several case series of cutaneous acral manifestations in patients with suspected or confirmed coronavirus disease 2019 (COVID‐19) have been reported. Indirect consequences of the ongoing pandemic on skin health have been reported, such as an increased frequency of irritant dermatitis related to repeated hand washing with soap, or occupational dermatoses in health care workers due to wearing gloves or masks (4, 5) . We describe here acral lesions observed in seven children (four girls) by the sixth week of the lockdown period in France. Although a larger case series would strengthen our hypothesis, we suggest that the change of daily habits in young children during the lockdown period may have increased the frequency of acral frictional dermatoses that are not directly due to the virus but rather to prolonged sessions spent playing on the floor. Acral cutaneous lesions in the Time of COVID-19
cord-260218-add4i1c9	2020	Recalcati(1) asserted that 20.4% of infected patients developed cutaneous manifestations and Galván‐Casas et al(2) have recently proposed 5 clinical patterns (pseudo‐chilblain, vesicular, urticarial, maculopapular and livedo/necrosis). 6 Purpura, Raynaud''s phenomenon, chilblain-like and erythema multiforme-like lesions in young asymptomatic patients have also been observed with this infection, although the connection with coagulopathy is unknown. 7, 8 Our patient presented with retiform purpura as a cutaneous manifestation of COVID-19 coagulopathy. 9 Our case highlights the concomitant presentation of cutaneous microthrombi presenting as retiform purpura and macrothrombi presenting as pulmonary thromboembolism in the setting of COVID-19 coagulopathy. From now on, we will have to include COVID-19 infection in the differential diagnosis of retiform purpura. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases Changes in Blood Coagulation in Patients with Severe Coronavirus Disease 2019 (COVID-19): a Meta-Analysis
cord-266475-t04pukea	2020	
cord-267748-uzt8a5nx	2020	title: Comment on "Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID‐19": Involvement of herpesvirus reactivations and adverse drug reactions in diverse cutaneous manifestations and overall disease severity of COVID‐19 We have read with great interest the publication by Herman, et al., which reported occurrence of drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome (DiHS), in a COVID-19 patient: 1 the patient developed DiHS/DRESS 17~18 days after starting azithromycin and hydroxychloroquine. Indeed, diverse clinical symptoms in DiHS/DRESS have been also reported as COVID-19-related cutaneous manifestations without confirming viral or drug etiologies: they include erythema multiforme, varicella, herpes zoster, pityriasis rosea, Kawasaki disease and urticaria, 5~7 in which herpesviruses, such as varicella-zoster virus (VZV) and human herpesvirus 6 (HHV-6), have been suggested to play a role.
cord-270500-5pkx94zu	2020	
cord-272321-znnipzym	2020	
cord-277110-e27lm7rr	2020	
cord-281703-6xwcxe8l	2020	
cord-282653-9n5sjn23	2020	key: cord-282653-9n5sjn23 considering urticarial lesions as a coronavirus disease 2019 (COVID‐19) associated skin manifestation(1). considering urticarial lesions as a coronavirus disease 2019 (COVID-19) associated skin manifestation 1 . A previous report of COVID19-related urticarial lesions had also been first published by Recalcati 2 . Since then, we began to observe different skin manifestations in patients with COVID-19 infection. We present the case of a patient with non-evanescent urticarial lesions and its clinicopathologic correlation. In our experience, these urticaria-like lesions may also appear in late phases and not only as early manifestations of COVID. But we must remember, that even today, when it seems that all of our patients are affected of COVID-19 and all the skin diseases may be related to it, we have to ground on clinicopathological correlation and to maintain the same quality standards that we used to have before SARS-Cov-2 appeared. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients
cord-282750-d9sb7o63	2020	
cord-283716-tleh9323	2020	The World Health Organization (WHO) has declared that Coronavirus disease 2019 (Covid-19) is a public health emergency of international concern as it continues to spread worldwide.1 After a median incubation period of 4 days, fever and cough are the two most common manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The World Health Organization (WHO) has declared that Coronavirus disease 2019 (Covid-19) is a public health emergency of international concern as it continues to spread worldwide. 1 After a median incubation period of 4 days, fever and cough are the two most common manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. [3] [4] [5] [6] [7] [8] [9] Herein, we describe a febrile rash as the only clinical manifestation of SARS-CoV-2 infection in a patient free from pulmonary symptoms. Firstly, Covid-19 disease can present with a distinctive rash, which is histologically similar but clinically different to classic viral exanthemata.
cord-290146-7fz9bj0b	2020	
cord-295551-ujnks5ox	2020	
cord-299143-vcfu79ij	2020	
cord-300546-s29ycc8i	2020	
cord-300995-tqz2bkdo	2020	
cord-301483-dsaltzdd	2020	
cord-303514-2ljmkabk	2020	
cord-304211-5uzqqbr4	2020	
cord-304946-fs02dxg5	2020	
cord-309507-oe4i6v5x	2020	Sexually transmitted infections (STIs) and diseases (STDs) affect millions of people every year worldwide(1). All rights reserved To the Editor, Sexually transmitted infections (STIs) and diseases (STDs) affect millions of people every year worldwide 1 . In Italy, data are provided by the Italian National Institute of Health (INIH) and reported to the European Centre for Disease Prevention and Control (ECDC) 2, 3 . In Italy, data are provided by the Italian National Institute of Health (INIH) and reported to the European Centre for Disease Prevention and Control (ECDC) 2, 3 . A total of 214 medical provisions were recorded after the lockdown: 13 patients required more than one healthcare service. The percentage of visits for prophylaxis declined after the lockdown, while visits for syphilis, gonococcal pharyngitis and inflammatory genital diseases increased significantly (Figure 1) . The percentage of patients requiring more than one provision increased from 2.1% to 6.5%, after the lockdown.
cord-310841-scg0h40b	2020	
cord-311523-erntrh3p	2020	
cord-314422-u2elzgl8	2020	
cord-322069-ys9s7l6e	2020	
cord-323334-ie7iklr4	2020	
cord-326737-b6gs9z4h	2020	title: STIs and the COVID‐19 pandemic: the lockdown does not stop sexual infections 2 During the lockdown (9 March -4 May), we diagnosed, by NAATs, 9 Chlamydia trachomatis infections and 2 Neisseria gonorrhoeae infections (one of these patients experienced a reinfection during the lockdown despite a negative-tested partner), and 4 cases of syphilis (Table 1) . Of these 15 STIs, 9 patients referred risky sexual behaviour during lockdown. Common sense suggests that social isolation and the closure of leisure venues may significantly reduce the opportunity for casual sexual encounters, and some authors suggested that quarantine and social distancing measures might reduce the incidence of STIs in the future. 4 Therefore, we suggest that visits of STI patients should not be cancelled, making use of teledermatology where possible and visiting any doubtful cases. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China The impacts of isolation measures against SARS-CoV-2 infection on sexual health
cord-327036-0260rrdx	2020	title: Cutaneous small‐vessel vasculitis associated with novel 2019 coronavirus SARS‐CoV‐2 infection (COVID‐19) The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has rapidly become a global health issue. This letter reports new dermatologic findings associated with a confirmed COVID‐19 case. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a global health issue. This letter reports new dermatologic findings associated with a confirmed COVID-19 case. Although the rRT-PCR from skin biopsy was negative, we believe that CSVV arising in the context of a COVID-19 infected person is no coincidence and should not be categorized as idiopathic. There are numerous reports of viral-induced vasculitis, either associated with cryoglobulin presence (as in HCV infected patients) 4 , or unrelated to them (as in individuals with influenza-vaccine-induced vasculitis) 5 . Petechial Skin Rash Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients
cord-339195-aq3hb68r	2020	A wide variety of cutaneous manifestations has recently been reported as COVID-19-related skin lesions, such as erythematous rash, acro-ischemia or chilblain-like lesions 1, 2 , which can be useful for the clinical diagnosis of COVID-19. Dear editor, A wide variety of cutaneous manifestations has recently been reported as COVID-19-related skin lesions, such as erythematous rash, acro-ischaemia or chilblain-like lesions, 1,2 which can be useful for the clinical diagnosis of COVID-19. In order to report a new clinical manifestation of SARS Coronavirus 2, we present a case of acute reactive genital ulcers in a COVID-19 patient. In order to report a new clinical manifestation of SARS Coronavirus 2, we present a case of acute reactive genital ulcers in a COVID-19 patient. One week later, the patient returned to our department referring improvement of the genital ulcers with pain reduction and complete resolution of the oral aphtha.
cord-340842-s00465sy	2020	
cord-341118-h5t87vf8	2020	
cord-341999-nosdj7b2	2020	Since December 2019, the pandemic coronavirus disease (2019‐nCoV; COVID‐19) has changed the approach to all dermatological diseases; in particular, psoriatic patients undergoing immunosuppressive drugs, such as biologics, can potentially show an increase risk of infection (1). However, few reports are available on the course of COVID‐19 infection in psoriatic patients treated with biological drugs (2). Since December 2019, the pandemic coronavirus disease (2019-nCoV; COVID-19) has changed the approach to all dermatological diseases; in particular, psoriatic patients undergoing immunosuppressive drugs, such as biologics, can potentially show an increase risk of infection (1) . However, few reports are available on the course of COVID-19 infection in psoriatic patients treated with biological drugs (2) . We describe a case series of four psoriatic patients treated with biologics who had a risk contact with COVID-19.
cord-342254-vdovpfu1	2020	
cord-344273-uztk6pc0	2020	
cord-345514-71qgingu	2020	
cord-346017-wforwxes	2020	
cord-346763-xdfl659q	2020